Evidence map›Paper›PMID 17001307›Full record

ArticleOncogene2007

Identification of an histone H3 acetylated/K4-methylated-bound intragenic enhancer regulatory for urokinase receptor expression.

H Wang, C Yan, I Asangani, H Allgayer, D D Boyd

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Endothelial-specific Enhancer as a Cis Element ofCurrent pharmaceutical design · 2024
    Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 4 countries.

H WangDepartment of Cancer Biology, MD Anderson Cancer Center, Houston, TX 77030, USA.
C Yan
I Asangani
H Allgayer
D D Boyd
The University of Texas MD Anderson Cancer Center · USHeidelberg University · DETranslational Research in Oncology · FR

Funding

UROKINASE RECEPTOR EXPRESSION--COLON CANCERR01CA058311 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BOYD, DOUGLAS D. · 1994 to 2010
$2.2M
Regulation of type IV collagenase expressionR01DE010845 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BOYD, DOUGLAS D. · 1994 to 2007
$1.7M
NCI NIH HHS R01 CA58311NIDCR NIH HHS DE10845
6 · The paper itself

Abstract

The transcriptionally regulated urokinase-type plasminogen activator receptor (u-PAR) contributes to cancer progression. Although previous studies have identified multiple 5' regulatory elements, these cis motifs cannot fully account for u-PAR expression prompting a search for hitherto uncharacterized regulatory elements. DNase I hypersensitivity and chromatin immunoprecipitation assays using u-PAR-expressing colon cancer cells indicated a hypersensitive region (+665/+2068) in intron 1 enriched with acetylated histone 3 (H3) and H3 methylated at lysine 4, markers of regulatory regions. The +665/+2068 region increased transcription from a u-PAR-promoter in an orientation- and distance-independent manner fulfilling the criteria of an enhancer. Optimal stimulation of the u-PAR promoter by phorbol ester required this enhancer. Systematic truncations combined with DNase I footprinting revealed two protected regions (+1060/+1099 and +1123/+1134) with deletion of the latter practically abolishing enhancer activity. The +1123/+1134 region harbored non-consensus activator protein-1 and Ets1 binding sites bound with c-Jun (and/or the related JunD/JunB) and c-Fos (and/or the related FosB/Fra-1/Fra-2) as revealed with chromatin immunoprecipitation. Further, nuclear extract from resected colon cancers showed elevated protein binding to a +1123/+1134-spanning probe coordinate with elevated u-PAR protein. Thus, we have defined a novel intragenic enhancer in the u-PAR gene required for constitutive and inducible expression.

Indexed as

Enhancer Elements, GeneticGene Expression Regulation, NeoplasticAcetylationChromatinChromatin ImmunoprecipitationColonic NeoplasmsDeoxyribonuclease IDNA FootprintingHistonesHumansIntronsPromoter Regions, GeneticReceptors, Cell SurfaceReceptors, Urokinase Plasminogen ActivatorTranscription FactorsChromatinDeoxyribonuclease IHistonesPLAUR protein, humanReceptors, Cell SurfaceReceptors, Urokinase Plasminogen ActivatorTranscription Factors

Identifiers

PMID17001307
OpenAlexW2040712273

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.